On the stock market since 2017, it operates in the world of health and science. It has 2,450 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
The company sells $844.6M a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 39 buys and 28 sells. Management buying with its own money is usually read as a good sign.
A loss of $70.3M against $844.6M in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
The stock trades 22% above the average analyst price target.
On our five-subject report card, VREX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: VREX has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.